Hikma Pharmaceuticals (LON:HIK) Stock Price Up 7.6% – Here’s Why

Shares of Hikma Pharmaceuticals PLC (LON:HIK) shot up 7.6% during mid-day trading on Tuesday . The company traded as high as GBX 1,670 and last traded at GBX 1,661. 1,945,266 shares changed hands during trading, a decline of 67% from the average session volume of 5,900,212 shares. The stock had previously closed at GBX 1,544.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on HIK shares. Jefferies Financial Group raised their price objective on Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the company a “buy” rating in a research note on Tuesday, May 5th. Berenberg Bank restated a “buy” rating and issued a GBX 1,800 price target on shares of Hikma Pharmaceuticals in a research report on Tuesday, April 28th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a GBX 195 price objective on shares of Hikma Pharmaceuticals in a research note on Monday, June 22nd. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Hikma Pharmaceuticals has a consensus rating of “Buy” and an average target price of GBX 1,687.

Hikma Pharmaceuticals Stock Down 2.2%

The company has a current ratio of 1.82, a quick ratio of 1.27 and a debt-to-equity ratio of 61.84. The company has a 50-day simple moving average of GBX 1,472.68 and a 200 day simple moving average of GBX 1,447.49. The company has a market cap of £3.36 billion, a P/E ratio of 8.82, a P/E/G ratio of 2.38 and a beta of 0.65.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.